What kind of pullback normally happens after something like this with a pharma company? Or is it expected to stabilize around this range?
VVUS - Vivus Inc - Page 7
Buying Yatchs was sooo 2011, 2012 is the year of islands! Just dont get caught with an island chain before the bubble burst
looks like FDA has approved Stendra, also known as Avanafil, a new drug to treat erectile dysfunction. Let the penetration continue!
Suppose to kicks in a lot faster. I guess every minute counts guys! haha
Citron has a whole report on VVUS. This explains the reason for the drop. My guess is that it might not stop until 20. Although how low it could go is anybody's guess.
Vivus's Intellectual Property Story: Serious Doubts about its IP Protection
"You can avoid reality, but you cannot avoid the consequences of avoiding reality."
- Ayn Rand (1905-1982)
While the company has been busy furthering their FDA submission and selling stock, Vivus has simply avoided confronting the reality that they might not even be able to go to market.
The foundation stone of Vivus' IP protection is a patent licensing deal signed a decade ago with a Dr. Najarian, an obesity doctor and researcher who filed as sole inventor for Qsymia's two-drug combo. One question that has been hanging over the company for years is the possibility of patent infringement on one of Qsymia's two active ingredients, topiramate, a patent held by Johnson & Johnson, who used to sell the drug as an obesity treatment before it went generic. It affords patent protection until 2017. It originally was filed by a researcher named Shank on June 29, 1996 (US PTO No. 6,071,537)
You do not have to be a patent attorney to read the title of the abstract:
"Anticonvulsant Derivatives Useful in Treating Obesity"
I just did some DD myself thinking of adding to my RRSP (401k)
Also saw this today